Login to Your Account

Expediting Drug Development

New FDA Breakthrough Therapy Designation Warmly Welcomed

By Peter Winter

Monday, September 23, 2013

It has been just over a year since the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed into law. Contained within the act is a breakthrough therapy (BT) designation, intended to expedite the development and review of drug candidates, which has certainly found favor among biopharmaceutical companies.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription